Autopsy report · NCT01120171

Myocet Plus Endoxan for Older Patients With Breast Cancer

“Due to poor accrual”

The sponsor’s own words in the registry.

Life of this trial

• Registered 8 months after it had already started.
• Ran for about 5 years 8 months before it stopped.
• 64 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Hellenic Oncology Research Group

Sponsor type

University, hospital or other

Conditions

Breast Cancer

Interventions

Cyclophosphamide; Liposomal-encapsulated doxorubicin

Participants

64

Sites

11

Countries

Greece

Trials that died the same way

• A Study of Olaparib and Durvalumab in Prostate Cancer
  “Due to low accrual” (93% match in meaning)
• Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic Multiple Myeloma
  “Lack of adequate accrual.” (84% match in meaning)
• INTERVAL: Ipilimumab and Nivolumab Combination Therapy: A Study of a Supervised or Semi-Supervised Exercise InteRVention or Usual Care With Functional Capacity and Quality of Life Evaluations in Subjects With Advanced or Metastatic RenAL Cell Carcinoma
  “Poor accrual” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.